These novel therapies , Semaglutide , represent a significant advancement in addressing obesity and conceivably related disorders. They all are categorized as GLP-1 pathway stimulators, indicating they to mimic the natural GLP-1 hormone , boosting metabolic production and reducing food intake. Although Retatrutide each functions relatively similarl